<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33973880</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-4156</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>1</Issue><PubDate><MedlineDate>2022 Jan-Mar 01</MedlineDate></PubDate></JournalIssue><Title>Alzheimer disease and associated disorders</Title><ISOAbbreviation>Alzheimer Dis Assoc Disord</ISOAbbreviation></Journal><ArticleTitle>An Agitated Patient With COVID-19 Infection and Early-onset Alzheimer Disease.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>84</EndPage><MedlinePgn>83-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WAD.0000000000000456</ELocationID><Abstract><AbstractText>Encephalopathy, delirium, and agitation are documented symptoms of coronavirus disease (COVID-19) infection, but research into the management of agitation in the setting of COVID-19 and pre-existing neuropsychiatric disease is ongoing. We present a 55-year-old male patient with early-onset Alzheimer disease and deteriorating mental and functional status who presented to our institution with agitation and persistent COVID-19 positivity on polymerase chain reaction testing. His agitation was improved through pharmacologic optimization including the avoidance of benzodiazepines and initiation of clonidine and prazosin, which temporally coincided with the resolution of his nearly 2-month long COVID-19 positivity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sykora</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Mayo Clinic Alix School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stonnington</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Neeta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimer Dis Assoc Disord</MedlineTA><NlmUniqueID>8704771</NlmUniqueID><ISSNLinking>0893-0341</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33973880</ArticleId><ArticleId IdType="pmc">PMC8876388</ArticleId><ArticleId IdType="doi">10.1097/WAD.0000000000000456</ArticleId><ArticleId IdType="pii">00002093-202201000-00013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ellul MA, Benjamin L, Singh B, et al. . Neurological associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera MA, Karamsetty L, Simpson SA. Coronavirus and its implications for psychiatry: a rapid review of the early literature. Psychosomatics. 2020;61:607&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251405</ArticleId><ArticleId IdType="pubmed">32943211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Li T, Barbarino P, et al. . Dementia care during COVID-19. Lancet. 2020;395:1190&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146671</ArticleId><ArticleId IdType="pubmed">32240625</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsteinsson AP, Drye LT, Pollock BG, et al. . Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4086818</ArticleId><ArticleId IdType="pubmed">24549548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilbul M, Paparone P, Kim AM, et al. . Psychopharmacology of COVID-19. Psychosomatics. 2020;61:411&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232075</ArticleId><ArticleId IdType="pubmed">32425246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baller EB, Hogan CS, Fusunyan MA, et al. . Neurocovid: pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020;61:585&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240270</ArticleId><ArticleId IdType="pubmed">32828569</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigham and Women&#x2019;s Hospital. Brigham and Women&#x2019;s Hospital COVID-19 clinical guidelines. 2020. Available at: https://covidprotocols.org/. Accessed November 30, 2020.</Citation></Reference><Reference><Citation>Gubbi S, Nazari MA, Taieb D, et al. . Catecholamine physiology and its implications in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:978&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598304</ArticleId><ArticleId IdType="pubmed">33128872</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns Hopkins University. Prazosin to prevent COVID-19 (PREVENT-COVID Trial) (PREVENT). NIH Clinical Trials. 2020. Available at: https://www.clinicaltrials.gov/ct2/show/NCT04365257. Accessed November 30, 2020.</Citation></Reference><Reference><Citation>Wang LY, Shofer JB, Rohde K, et al. . Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr psychiatry Off J Am Assoc Geriatr Psychiatry. 2009;17:744&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842091</ArticleId><ArticleId IdType="pubmed">19700947</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>